[go: up one dir, main page]

AU2002328173A1 - Omoxin agonists and antagonists for use in the treatment of metabolic disorders - Google Patents

Omoxin agonists and antagonists for use in the treatment of metabolic disorders

Info

Publication number
AU2002328173A1
AU2002328173A1 AU2002328173A AU2002328173A AU2002328173A1 AU 2002328173 A1 AU2002328173 A1 AU 2002328173A1 AU 2002328173 A AU2002328173 A AU 2002328173A AU 2002328173 A AU2002328173 A AU 2002328173A AU 2002328173 A1 AU2002328173 A1 AU 2002328173A1
Authority
AU
Australia
Prior art keywords
omoxin
agonists
antagonists
treatment
metabolic disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002328173A
Inventor
Kristen Briggs
Deno Dialynas
John Lucas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Publication of AU2002328173A1 publication Critical patent/AU2002328173A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002328173A 2001-08-07 2002-08-05 Omoxin agonists and antagonists for use in the treatment of metabolic disorders Abandoned AU2002328173A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31073101P 2001-08-07 2001-08-07
US31078401P 2001-08-07 2001-08-07
US60/310,731 2001-08-07
US60/310,784 2001-08-07
US33394601P 2001-11-19 2001-11-19
US60/333,946 2001-11-19
PCT/IB2002/003344 WO2003013578A1 (en) 2001-08-07 2002-08-05 Omoxin agonists and antagonists for use in the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
AU2002328173A1 true AU2002328173A1 (en) 2003-02-24

Family

ID=27405471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002328173A Abandoned AU2002328173A1 (en) 2001-08-07 2002-08-05 Omoxin agonists and antagonists for use in the treatment of metabolic disorders

Country Status (2)

Country Link
AU (1) AU2002328173A1 (en)
WO (1) WO2003013578A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012282B1 (en) 1997-09-12 2007-04-18 Biogen Idec MA Inc. Cysteine rich receptors-train
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
US7769765B2 (en) 2006-07-25 2010-08-03 Lockheed Martin Corporation Method and system for sorting mail

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999021577A1 (en) * 1997-10-29 1999-05-06 Otsuka Pharmaceutical Co., Ltd. Compositions inhibiting smooth muscle proliferation, method for the diagnosis of arteriosclerosis, and kits therefor
EP1085897A4 (en) * 1998-05-21 2003-03-12 Smithkline Beecham Corp Acrp30r1l, a homolog of acrp30 (30 kd adipocyte complement-related protein)
EP1177296A2 (en) * 1999-05-11 2002-02-06 Incyte Genomics, Inc. Extracellular matrix and adhesion-associated proteins
CA2374387A1 (en) * 1999-05-27 2000-12-07 Zymogenetics, Inc. Adipocyte complement related protein homolog zacrp7
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
DE60135439D1 (en) * 2000-01-14 2008-10-02 Serono Genetics Inst Sa OBG3 GLOBULAR HEAD AND ITS USES FOR REDUCING BODY WEIGHT

Also Published As

Publication number Publication date
WO2003013578A1 (en) 2003-02-20
WO2003013578A8 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
AU2002339691A1 (en) Agonists and antagonists of prolixin for the treatment of metabolic disorders
AU2003223579A1 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
AU2003286285A1 (en) Use of fgf-18 in the diagnosis and treatment of memory disorders
IL159879A0 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
AU2003250831A1 (en) Use of hec1 antagonists in the treatment of proliferative disorders and cancer
AU2001248971A1 (en) Use of npy y1 receptor agonists in the treatment of pain conditions
AU2002339673A1 (en) Agonists and antagonists of ryzn for the treatment of metabolic disorders
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
AU2002339682A1 (en) Emergen agonists and antagonists for use in the treatment of metabolic disorders
AU2003293500A1 (en) Lactoferrin in the reduction of pain
AU2002339688A1 (en) Glucoset agonists and antagonists for use in the treatment of metabolic disorders
AU2002321774A1 (en) Agonists and antagonists of contabix for use in the treatment of metabolic disorders
AU2002339674A1 (en) Ditacin agonists and antagonists for use in the treatment of metabolic disorders
AU2002334250A1 (en) Xafinix agonists and antagonists for use in the treatment of metabolic disorders
AU2002313579A1 (en) Agonists and antagonists of famoset for use in the treatment of metabolic disorders
AU2002339689A1 (en) Dexar agonists and antagonists for use in the treatment of metabolic disorders
AU2002328172A1 (en) Agonists and antagonists of modumet for use in the treatment of metabolic disorders
AU2002313581A1 (en) Lypergix agonists and antagonists for use in the treatment of metabolic disorders
AU2002321764A1 (en) Genobix agonists and antagonists for use in the treatment of metabolic disorders
AU2002339679A1 (en) Glucomin agonists and antagonists for use in the treatment of metabolic disorders
AU2002313578A1 (en) Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders
AU2002324288A1 (en) Agonists and antagonists of genoxin for use in the treatment of metabolic disorders
AU2002324296A1 (en) Agonists and antagonists of energen for use in the treatment of metabolic disorders
AU2002324299A1 (en) Genoxit agonists and antagonists for use in the treatment of metabolic disorders
AU2002328096A1 (en) Faxigen agonists and antagonists in the treatment of metabolic disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase